You are here

NOVEL THERAPEUTIC APPROACH TO PSORIASIS

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: PHS2001-2
Agency Tracking Number: 2R42AR044767-02A2
Amount: $315,774.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2001
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
1016 LAKEVIEW WAY REDWOOD CITY, CA 94062-3446
REDWOOD CITY, CA 94062
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 HARRIHAR PERSHADSINGH
 (415) 366-5512
 BETHESDAPH@AOL.COM
Business Contact
Phone: (415) 357-9796
Email: BETHESDAPH@AOL.COM
Research Institution
 UNIVERSITY OF MICHIGAN
 
UNIVERSITY OF MICHIGAN
ANN ARBOR, MI 48161
United States

 Nonprofit College or University
Abstract

DESCRIPTION (Applicant's abstract): Psoriasis is a common, inflammatory disease
of the skin characterized by hyper-proliferation of keratinocytes. A variety of
antipsoriatic therapies are available, however, due to problems with side
effects and variability in clinical response, intense clinical and commercial
interest remains in the development of new treatments. Thiazolidinediones, a
novel class of compounds that activate the nuclear hormone receptor PPAR gamma,
have recently been found to reversibly inhibit the proliferation of both normal
and psoriatic human keratinocytes in vitro, and ameliorate the histologic
abnormalities of psoriatic skin in organ culture and in the scid mouse/human
skin transplant model of psoriasis. In the current proposal, we will: 1)
perform pilot studies of the antipsoriatic effects of orally administered
thiazolidinediones in humans; 2) investigate the cellular mechanisms that
mediate the antipsoriatic effects of thiazolidinediones, and 3) investigate the
antipsoriatic potential of a recently developed series of novel
thiazolidinediones that are expected to be more effective than existing
compounds with respect to ameliorating the epidermal inflammation and
hyperproliferation that characterizes psoriasis. By investigating clinical
efficacy, by addressing therapeutic mechanisms, and by testing novel
thiazolidinediones, the current Phase II studies will significantly advance the
potential for Phase III commercial development of thiazolidinediones in the
treatment of psoriasis.
PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government